Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Open Access
- 13 August 2015
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 126 (7) , 858-862
Abstract
Key Points. In MM patients, stringent CR criteria, in particular the sFLC ratio, do not predict significantly better outcome among MM patients in conventionalKeywords
This publication has 21 references indexed in Scilit:
- Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institutionHaematologica, 2013
- Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patientsLeukemia, 2012
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA TrialJournal of Clinical Oncology, 2010
- The role of complete response in multiple myelomaBlood, 2009
- Serum Free Light Chain Ratio, Total κ/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaClinical Chemistry, 2009
- Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myelomaHaematologica, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcomeBlood, 2002
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998